Enovate Biolife Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 18-07-2024
- Paid Up Capital ₹ 2.50 M
as on 18-07-2024
- Company Age 14 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.00 M
as on 18-07-2024
- Revenue -10.10%
(FY 2023)
- Profit -27.60%
(FY 2023)
- Ebitda -30.64%
(FY 2023)
- Net Worth 33.60%
(FY 2023)
- Total Assets 26.34%
(FY 2023)
About Enovate Biolife
The Company is engaged in the Life Science Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹8.00 M.
Rajesh Chaudhary, Jayesh Chaudhary, and Latha Chaudhary serve as directors at the Company.
- CIN/LLPIN
U73100MH2009PTC197701
- Company No.
197701
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Dec 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Enovate Biolife Private Limited offer?
Enovate Biolife Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Diabetes Medicine, Health Care Service, Common Disease Medicines, Pharmaceutical Tablets, Health Club Services, Fitness Club, Herbal Extracts, Plant Extracts, Medical Surgery & Treatment Centres.
Who are the key members and board of directors at Enovate Biolife?
Board Members(3)
Financial Performance and Corporate Structure Insights of Enovate Biolife.
Enovate Biolife Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 10.1% decrease. The company also saw a substantial fall in profitability, with a 27.6% decrease in profit. The company's net worth Soared by an impressive increase of 33.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Enovate Biolife?
In 2023, Enovate Biolife had a promoter holding of 98.00% and a public holding of 2.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vedic Lifesciences Private Limited
Active
19 years 6 months Rajesh Chaudhary, Jayesh Chaudhary and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Ing Vysya Bank Limited Creation Date: 28 Sep 2013 | ₹8.00 M | Open |
How Many Employees Work at Enovate Biolife?
Unlock and access historical data on people associated with Enovate Biolife, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Mar 29, 2013, Enovate Biolife has raised a total of ₹ 4.4 M, with the most recent deal valued at ₹ 1.5 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
